Compound Radar

United Therapeutics Corporation (UTHR) Stock Analysis

Price $591.20
Market cap $25.36B
Next earnings Nov 4, 2026
Entry status Watch $481.34–$511.12

Last updated Oct 27, 2026

Health Check

Last analyzed Oct 23, 2026

78
78/100 Elite Quality
  • Financial Health 85
  • Profitability 80
  • Business Quality 75
  • Balance Sheet 65
  • Cash Flow 80

Why this rating?

Health 78/100 — Elite Quality

Strongest Financial Health 85/100
Softest Balance Sheet 65/100
Watch

Worth tracking, but timing is mixed — not a clear setup yet.

Company overview

United Therapeutics Corporation (UTHR) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector. Compound Radar rates United Therapeutics Corporation 78/100 (Elite Quality) due to high business quality, manageable leverage, and attractive valuation.

Investment profile

  • Quality High
  • Growth Soft
  • Balance Sheet Adequate
  • Valuation Attractive

Financial highlights

Valuation

  • P/E 21.17
  • Forward P/E 17.33
  • PEG 2.22
  • EV/Revenue 7.22

Profitability

  • Revenue Growth -1.9%
  • Gross Margin 86.1%
  • Operating Margin 42.2%
  • Net Margin 41.6%
  • ROE 19.3%

Financial strength

  • Cash $2.66B
  • Debt $0.00
  • Net Cash $2.66B
  • Free Cash Flow $1.04B
  • Current Ratio 5.73

Similar companies

Peers in Drug Manufacturers - Specialty & Generic, ranked by Financial Health.

Company Ticker
Price Current price

Latest quoted price for the name. Helps anchor the setup in today’s market level.

Health Entry

View all in Drug Manufacturers - Specialty & Generic →

FAQ

How Compound Radar scores and tracks United Therapeutics Corporation (UTHR).

View Methodology & FAQ →